SAN FRANCISCO, CA, October 20, 2026 (EZ Newswire) — Clinical Maestro today announced the launch of VISION Plus, the second major release of its AI-native intelligence platform for pharmaceutical business operations, following the introduction of Source Plus in September 2026.
Building on the platform’s specialized AI architecture, proprietary pharmaceutical intelligence and differentiated data foundation, VISION Plus introduces comprehensive KPI automation, performance management and continuous vendor oversight for pharmaceutical companies and their external service providers.
Pharmaceutical companies increasingly depend on CROs and specialized providers, yet vendor performance management remains fragmented. KPIs are often collected in spreadsheets and manually assembled scorecards, while risks, audits, governance decisions and corrective actions are managed separately. VISION Plus connects these activities in one environment, integrating KPI management with vendor qualification, governance, risk, issues, audits, CAPAs and actions.
“A KPI turning red is only a signal. What matters is understanding why it changed, whether the pattern exists elsewhere, what risks or issues are connected to it, and what action followed,” said Anca Copaescu, CEO of Clinical Maestro. “VISION Plus allows organizations to move beyond reporting KPIs toward understanding and governing vendor performance.”
A Connected Approach to Vendor Performance
VISION Plus introduces standardized, version-controlled KPI libraries; configurable performance thresholds; automated data collection and review workflows; cross-vendor and cross-study analysis; and governance escalation capabilities. Sponsors gain greater consistency and traceability in oversight, while CROs benefit from a more structured and collaborative performance-management environment.
Maestro AI is embedded throughout these workflows, enabling users to investigate performance trends, analyze governance evidence, identify risks and generate Insight Reports, including Tier 1 Vendor Performance, CRO Category Risk Summary, Quarterly Governance Brief and Executive Vendor Health.
Expanding an AI-Native Intelligence Platform for Clinical Business Operations
With Source Plus launched in September and now VISION Plus, Clinical Maestro is extending its AI-native intelligence architecture across the clinical outsourcing lifecycle. Built on nine years of specialized pharmaceutical business operations expertise, the platform combines proprietary AI agents, purpose-built data structures, accumulated industry knowledge, sourcing and governance methodologies, and benchmarking intelligence with customer-specific organizational data.
Unlike generic AI assistants added to traditional SaaS applications, Maestro AI is embedded directly into specialized business workflows, enabling users to interpret pharmaceutical-specific information, analyze complex relationships, identify patterns and generate actionable insights.
“Source Plus introduced our AI-native intelligence platform in September. With VISION Plus, just weeks later, we are demonstrating how that architecture extends across clinical business operations,” said Paulo Carvalho, chief operating officer of Clinical Maestro. “Our differentiation is not simply AI. It is nine years of pharmaceutical expertise, specialized workflows and data intelligence, now activated through proprietary AI agents. We are building a fundamentally different kind of technology company.”
About Clinical Maestro
Clinical Maestro is an AI-native intelligence technology company specializing in pharmaceutical business operations. Its platform combines proprietary AI agents, pharmaceutical expertise, specialized data intelligence and connected workflows to support clinical development planning, R&D sourcing, vendor governance and financial oversight. For more information about VISION Plus or to request a demonstration, visit clinicalmaestro.com.
Media Contact
Ema Hafner
Marketing Director
ehafner@clinicalmaestro.com
SOURCE: Clinical Maestro
